Clinical trial
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
NCT00003748 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003748 |
|---|---|
| Title | Irinotecan in Treating Patients With Esophageal or Stomach Cancer |
| Official title | Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | Pharmacia and Upjohn Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Cancer, Gastric Cancer |
| Intervention type | Drug |
| Interventions | irinotecan hydrochloride |
| Enrollment | 40 |
| Start date | Aug 1, 1998 |
| Primary completion | Jun 1, 2000 |
| Completion | Jan 1, 2005 |
| First posted | Jul 22, 2004 |
| Last update posted | Aug 3, 2020 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: